• Q1 2025 unaudited revenue of approximately $186 million, up 62% YOY
• Illuccix® global sales of $151 million, up 35% YOY
• Reaffirmed FY 2025 revenue guidance of $770 million to $800 million

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) reported an unaudited revenue of approximately $186 million for the first quarter of 2025 (Q1 2025), representing a 62% increase over the prior year corresponding quarter (Q1 2024: $115M) and a 31% quarter-over-quarter increase (Q4 2024: $142 million). This included $151 million from global sales of Illuccix®, up 35% over Q1 2024 ($112 million) and a 9% quarter-over-quarter increase (Q4 2024: $139 million). The company also generated $33 million in revenue from the RLS Radiopharmacies acquisition, which was completed on 27 January 2025. Telix reaffirmed its FY 2025 revenue guidance of $770 million to $800 million, reflecting revenue from Illuccix® sales in jurisdictions with marketing authorization and 11 months of revenue from RLS. The company continues to make progress on its pipeline, with the Phase 3 trial of TLX591 for prostate cancer on track, positive preliminary results from the IPAX-Linz Phase 2 trial of TLX101 for brain cancer, and the FDA approving the New Drug Application for Gozellix® and accepting the Biologics License Application for TLX250-CDx for kidney cancer. Telix also completed the acquisition of a suite of clinically validated FAP-targeting therapeutic and precision medicine candidates, as well as the therapeutics assets of antibody engineering company ImaginAb, Inc. Additionally, Telix announced the development and validation of a breakthrough generator technology for the production of lead-212, a promising alpha-emitting therapeutic radioisotope.

Telix confirms FY 2025 revenue guidance of $770 million to $800 million, reflecting revenue from Illuccix® sales in jurisdictions with a marketing authorization, and 11 months of revenue from RLS. Revenue guidance is expected to be updated at the appropriate time, following and subject to reimbursement for Gozellix® in the United States and Illuccix® in ex-U.S. markets.

Telix is the only company with two FDA-approved PSMA-PET imaging agents - Illuccix and Gozellix - enabling the company to broaden patient reach and maximize choice for its customers. The expansion of Telix's commercial portfolio and launches of Illuccix into new international markets provides a foundation to diversify and grow revenue globally, while the company continues to deliver on multiple catalysts in its pipeline.